Home » Moderna’s COVID-19 Vaccine Grabs Fast-Track Designation from FDA
Moderna’s COVID-19 Vaccine Grabs Fast-Track Designation from FDA
The FDA has granted Moderna’s COVID-19 vaccine candidate a fast-track designation, making it the first potential vaccine to receive the agency’s expedited review status.
The company is finalizing the protocol for a phase 3 study of the vaccine, mRNA-1273. The phase 3 trial is expected to begin in early summer.
Moderna previously received fast-track designations for three other messenger RNA vaccine programs, including its investigational Zika vaccine.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May